162 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 162 shares of the biopharmaceutical company’s stock, valued at approximately $45,000.

A number of other institutional investors also recently modified their holdings of the company. Los Angeles Capital Management LLC boosted its stake in Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after purchasing an additional 135,829 shares during the period. AQR Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 92.5% in the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock valued at $65,862,000 after acquiring an additional 130,482 shares during the period. Deerfield Management Company L.P. Series C acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $29,111,000. Avoro Capital Advisors LLC increased its position in Alnylam Pharmaceuticals by 33.3% during the second quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $97,200,000 after acquiring an additional 100,000 shares during the period. Finally, Telemark Asset Management LLC acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at $27,503,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $253.74 on Friday. The company has a 50 day moving average price of $271.93 and a 200 day moving average price of $240.19. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The stock has a market capitalization of $32.73 billion, a PE ratio of -96.85 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. The firm’s revenue for the quarter was down 33.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.15 earnings per share. Analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Analysts Set New Price Targets

ALNY has been the topic of several research reports. Royal Bank of Canada restated an “outperform” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Wells Fargo & Company boosted their price target on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. Citigroup raised their price objective on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Bank of America boosted their price objective on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $296.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. One research analyst has rated the stock with a sell rating, six have given a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $298.09.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the sale, the chief marketing officer now owns 17,457 shares of the company’s stock, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 5,219 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the transaction, the chief executive officer now directly owns 78,880 shares in the company, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 8,370 shares of company stock worth $2,100,703 in the last quarter. 1.50% of the stock is owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.